Assessment and management of newly diagnosed classical Hodgkin lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance

Tara Cochrane; Belinda A Campbell; Shane A Gangatharan; Maya Latimer; Richard Khor; David R H Christie; Michael Gilbertson; Sumita Ratnasingam; Emma Palfreyman; Hui-Peng Lee; Judith Trotman; Mark Hertzberg; Michael Dickinson

doi:10.1111/imj.15503

Assessment and management of newly diagnosed classical Hodgkin lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance

Intern Med J. 2021 Dec;51(12):2119-2128. doi: 10.1111/imj.15503. Epub 2021 Nov 22.

Authors

Tara Cochrane^{1

2}, Belinda A Campbell^{3

4

5}, Shane A Gangatharan^{6

7}, Maya Latimer⁸, Richard Khor⁹, David R H Christie^{10

11}, Michael Gilbertson^{12

13

14}, Sumita Ratnasingam¹⁵, Emma Palfreyman¹⁶, Hui-Peng Lee¹⁷, Judith Trotman^{18

19}, Mark Hertzberg^{20

21}, Michael Dickinson^{5

22}

Affiliations

¹ Department of Haematology, Gold Coast University Hospital, Gold Coast, Queensland, Australia.
² School of Medicine, Griffiths University, Gold Coast, Queensland, Australia.
³ Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
⁴ Department of Clinical Pathology, University of Melbourne, Parkville, Victoria, Australia.
⁵ Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
⁶ Fiona Stanley Hospital, Perth, Western Australia, Australia.
⁷ University of Western Australia, Perth, Western Australia, Australia.
⁸ ACT Pathology and Canberra Hospital, Canberra, Australian Capital Territory, Australia.
⁹ Austin Hospital, Melbourne, Victoria, Australia.
¹⁰ Genesiscare, Gold Coast, Queensland, Australia.
¹¹ Bond University, Gold Coast, Queensland, Australia.
¹² Monash Health, Melbourne, Victoria, Australia.
¹³ School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia.
¹⁴ Department of Haematology and Oncology, Western Health, Melbourne, Victoria, Australia.
¹⁵ Andrew Love Cancer Centre, University Hospital Geelong, Geelong, Victoria, Australia.
¹⁶ Royal Darwin Hospital, Darwin, Northern Territory, Australia.
¹⁷ Flinders Medical Centre, Adelaide, South Australia, Australia.
¹⁸ Concord Repatriation General Hospital, Sydney, New South Wales, Australia.
¹⁹ University of Sydney, Sydney, New South Wales, Australia.
²⁰ Department of Haematology, Prince of Wales Hospital, Sydney, New South Wales, Australia.
²¹ University of NSW, Sydney, New South Wales, Australia.
²² Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia.

PMID: 34505342
DOI: 10.1111/imj.15503

Abstract

The management of Hodgkin lymphoma (HL) has undergone significant changes in recent years. Due to the predilection of HL to affect younger patients, balancing cure and treatment-related morbidity is a constant source of concern for physicians and patients alike. Positron emission tomography adapted therapy has been developed for both early and advanced stage HL to try and improve the outcome of treatment, while minimising toxicities. The aim of this review is to digest the plethora of studies recently conducted and provide some clear, evidence-based practice statements to simplify the management of HL.

Keywords: HL; Hodgkin lymphoma; PET adapted; chemotherapy; radiotherapy.

Publication types

Review

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Consensus
Disease-Free Survival
Hodgkin Disease* / diagnostic imaging
Hodgkin Disease* / therapy
Humans
Positron-Emission Tomography / methods
Prognosis